Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: Malignant glial brain tumors consistently overexpress neurokinin type 1 receptors. In classic seed-based brachytherapy, one to several rigid 125I seeds are inserted, mainly for the treatment of small low-grade gliomas. The complex geometry of rapidly proliferating high-grade gliomas requires a diffusible system targeting tumor-associated surface structures to saturate the tumor, including its margins. Experimental Design: We developed a new targeting vector by conjugating the chelator 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid to Arg1 of substance P, generating a radiopharmaceutical with a molecular weight of 1,806 Da and an IC50 of 0.88 ± 0.34 nmol/L. Cell biological studies were done with glioblastoma cell lines. neurokinin type-1 receptor (NK1R) autoradiography was done with 58 tumor biopsies. For labeling, 90Y was mostly used. To reduce the “cross-fire effect” in critically located tumors, 177Lut and 213Bi were used instead. In a pilot study, we assessed feasibility, biodistribution, and early and long-term toxicity following i.t. injection of radiolabeled 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid substance P in 14 glioblastoma and six glioma patients of WHO grades 2 to 3. Results: Autoradiography disclosed overexpression of NK1R in 55 of 58 gliomas of WHO grades 2 to 4. Internalization of the peptidic vector was found to be specific. Clinically, the radiopharmeutical was distributed according to tumor geometry. Only transient toxicity was seen as symptomatic radiogenic edema in one patient (observation period, 7-66 months). Disease stabilization and/or improved neurologic status was observed in 13 of 20 patients. Secondary resection disclosed widespread radiation necrosis with improved demarcation. Conclusions: Targeted radiotherapy using diffusible peptidic vectors represents an innovative strategy for local control of malignant gliomas, which will be further assessed as a neoadjuvant approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569
Self-citation
Cited by
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 370
Self-citationBanerjee, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Chemical Reviews · doi:10.1021/cr500171e · Cited by 321
An overview of targeted alpha therapy
Kim, Y.-S., & Brechbiel, M. W. (2012) · Tumor Biology · doi:10.1007/s13277-011-0286-y · Cited by 278
The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond
Elgqvist, J., Frost, S., Pouget, J.-P., & Albertsson, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00324 · Cited by 194
Metadata
- Authors
- Kneifel, S., Cordier, D., Good, S., Ionescu, M. C. S., Ghaffari, A., Hofer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., Arnold, M., Mueller-Brand, J., Maecke, H. R., Reubi, J. C., & Merlo, A.
- Venue
- Clinical Cancer Research
- Published
- 2006-06-15
- Volume
- 12
- Issue
- 12
- Pages
- 3843-3850
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2141104573
- Cited by
- 154
- References
- 2
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2820
- The paper
- Kneifel, S., Cordier, D., Good, S., Ionescu, M. C. S., Ghaffari, A., Hofer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., Arnold, M., Mueller-Brand, J., Maecke, H. R., Reubi, J. C., & Merlo, A. (2006). Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2820
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.